Standard BioTools Inc. Total Liabilities and Equity
Standard BioTools Inc. (LAB) had Total Liabilities and Equity of $627.22 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-08-05
- 2026-06-30: Liabilities and Equity $627.22M.
- 2026-03-31: Liabilities and Equity $639.11M.
- 2025-12-31: Liabilities and Equity $567.75M.
- 2025-09-30: Liabilities and Equity $539.64M.
| Period end | Liabilities and Equity | Liabilities and Equity as first filed |
|---|---|---|
| 2026-06-30 | $627.22M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $639.11M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $567.75M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $539.64M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $556.97M 10-Q · filed 2025-08-15 | |
| 2025-03-31 | $579.60M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $612.35M 10-K · filed 2026-03-16 | $612.34M 10-K · filed 2025-03-11 |
| 2024-09-30 | $681.54M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $708.73M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $777.67M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $323.07M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $339.29M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $355.83M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $371.65M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $390.31M 10-K · filed 2024-03-01 | |
| 2022-09-30 | $414.92M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $441.12M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $271.94M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $275.21M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $282.19M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $289.31M 10-Q · filed 2021-08-06 | |
| 2021-03-31 | $305.20M 10-Q · filed 2021-05-07 | |
| 2020-12-31 | $324.76M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $322.98M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $282.35M 10-Q · filed 2020-08-07 | |
| 2020-03-31 | $290.22M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $264.81M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $269.39M 10-Q · filed 2019-11-08 | |
| 2019-06-30 | $283.79M 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $291.45M 10-Q · filed 2019-05-07 | |
| 2018-12-31 | $303.65M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $252.29M 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $259.10M 10-Q · filed 2018-08-08 | |
| 2018-03-31 | $269.70M 10-Q · filed 2018-05-08 | |
| 2018-01-01 | $287.71M 10-K · filed 2019-03-18 | |
| 2017-12-31 | $287.35M 10-K · filed 2019-03-18 | |
| 2017-09-30 | $292.00M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $278.71M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $292.47M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $306.39M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $320.42M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $342.03M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $354.44M 10-Q · filed 2016-05-09 | |
| 2015-12-31 | $370.05M 10-K · filed 2017-03-03 | $371.06M 10-K · filed 2016-02-29 |
| 2015-09-30 | $378.49M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $389.13M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $395.03M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $407.56M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $410.39M 10-Q · filed 2014-11-06 | |
| 2014-06-30 | $417.75M 10-Q · filed 2014-08-04 | |
| 2014-03-31 | $424.72M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $116.92M 10-K · filed 2015-02-26 | |
| 2013-09-30 | $114.24M 10-Q · filed 2013-11-07 | |
| 2013-06-30 | $111.97M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $113.24M 10-Q · filed 2013-05-09 | |
| 2012-12-31 | $113.73M 10-K · filed 2014-03-12 | |
| 2012-09-30 | $117.09M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $64.93M 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $70.67M 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $79.33M 10-K · filed 2013-03-12 | |
| 2011-09-30 | $82.60M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $85.66M 10-Q · filed 2011-08-09 | |
| 2010-12-31 | $24.80M 10-K · filed 2012-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |